Business Wire

CA-PATIENT-SAFETY

10.11.2021 14:02:09 CET | Business Wire | Press release

Share
Seven Healthcare Industry "High Reliability Organization Champions" Recognized by Patient Safety Movement Foundation

Medical errors claim the lives of nearly three million individuals across the globe every year. In any other high-risk industry, like aviation and nuclear power, these numbers would not be acceptable. Yet, the healthcare industry has continued to allow these events to occur—putting patients and staff at risk. The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, believes that to reach this goal healthcare organizations that provide care to patients need to commit to operating as highly reliable organizations (HROs) to reduce preventable medical harm. To support this, PSMF launched its new HRO Champion Program and is excited to recognize the first seven healthcare organizations that have committed to this effort. These HRO Champions include: Kaiser Permanente Northern California, Parrish Medical Center (Titusville, Fla.), Hospital Puebla (Puebla, Mexico), Hospitales Star Medica (Mexico City, Mexico), Hospital Materno Infantil Irapuato (Irapuato, Mexico), Hospital de Especialidades Pediatrico Leon (San Jose del Potrero, Mexico) and Hospital Español (Granada, Mexico).

“The pandemic exposed gaps in the global healthcare system, which forced us to examine the processes in place and identify ways we can prioritize patient safety,” stated Dr. Mike Ramsay, CEO of PSMF. “We are proud to recognize and unite healthcare systems that share this mission and provide them resources to help improve their processes and eliminate preventable harm in their organizations.”

The new HRO Champions program puts an emphasis on data transparency, as this is a critical component to achieving zero harm and improving patient safety. To participate, hospitals and healthcare organizations commit to sharing their adverse event and near-miss data, once annually, to measure the impact of improvements in the network over time. Not only does transparency hold health systems accountable, but it also makes it easier for patients to access safety information to make informed healthcare decisions.

“We are honored to have been designated as HRO Champions by the Patient Safety Movement Foundation, in which we have found a valuable ally to continue improving our care processes,” stated Jose Testas Anton, vice president of Hospital Español. “At Hospital Español, we believe that being able to share and collaborate with other health systems and provide information related to patient safety outside the walls of our organization will help generate collaborative learning and promote patient safety around the world.”

“We are pleased to be recognized for our unwavering commitment to provide safe and reliable patient care and commend our staff for being strong advocates for and partnering with their patients to prevent unnecessary harm,” said Robin Betts, vice president of safety, quality and regulatory services for Kaiser Permanente Northern California. “Our hospitals are among the country’s highest performing for minimizing patient injuries, medication errors and infections. We have processes in place, which closely align with the Patient Safety Movement Foundation to highlight potential safety issues for our care teams who focus every day on protecting the health of their patients, keeping them safe from harm and providing the highest quality care.”

By committing to zero harm, healthcare organizations are eligible for many different benefits, including free coaching, workshops, publicity and other tools. HRO Champions are announced every month and can submit data any time throughout the year to be eligible. Learn more about how to become a HRO Champion: https://patientsafetymovement.org/take-action/organizational-action/going-above-and-beyond/hro-champions/

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye